Tags Cellinity Battery
Tag: Cellinity Battery
BioLargo reports stronger AEC performance at Lake Stockholm as PFAS treatment, CupriDyne®, Aquatech, and Clyra shape its next commercial phase.
BioLargo expands PFAS, Clyra, and BLEST operations while working to recover from the financial fallout tied to Pooph®.
BioLargo enters early commercialization with Clyra and PFAS, but steep revenue loss from Pooph® collapse leaves execution and scaling critical in 2026.
BioLargo's Q3 2025 report shows tech traction in PFAS, Clyra™, and Cellinity™ — but monetization remains elusive post-Pooph® fallout.
BioLargo's Q2 exposes value-chain gaps—regulatory lags, partner dependency, and no clear path from validation to revenue.
BioLargo’s growth hinges on its AEC, Clyra™, and Pooph® innovations, but delays and cash burn turn Q2–Q3 into a critical test for its long-term ambitions.
